
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc. has demonstrated robust revenue growth through its portfolio of royalty and healthcare assets, with annual sales for Giapreza increasing by 33% from 2023 to 2024 and maintaining significant growth for Xerava above 20% since acquisition. The company's strategic acquisitions have outperformed their previous owners, with Giapreza and Xerava's annualized run rates nearly doubling since Innoviva acquired them in August 2022. Additionally, Giapreza's net sales rose from $33.4 million in 2021 to $41.3 million in 2023, reflecting a 24% increase, and are projected to reach $55 million in 2024, highlighting the company's effective asset management and sales strategies.
Bears say
Innoviva Inc. faces a negative outlook primarily due to projected declines in royalties from its key products, with expectations of an average year-over-year decrease of -8% for Relvar/Breo and -4% for Anoro over the next eight years. Additionally, the anticipated loss of exclusivity for Giapreza in 2034 further compounds risks to future revenue streams, as it is expected to significantly impact revenue generation in critical care and infectious disease markets. The company may encounter increased competitive pressures over time, although the difficulty of genericizing its drugs due to challenges in engineering competing delivery devices offers some mitigation against severe declines, yet overall, the financial trends suggest weakening performance prospects.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares